A 3-Dimensional View of Access to Licensed and Subsidized Medicines under Single-Payer Systems in the US, the UK, Australia and New Zealand

By Ragupathy Rajan  

PharmacoEconomics, Vol. 30, Iss. 11, 2012-11 ,pp. : 1051-1065

Adis International

Access to resources Recommend Favorite

The use of complementary and alternative medicines (CAM) in New Zealand children aged < 12 years is high, and disclosure rates low

By  

Inpharma, Vol. 1, Iss. 1584, 2007-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

The expected start time for a joint regulatory scheme for therapeutic products in Australia and New Zealand (NZ) is now the second half of 2007

By  

Reactions Weekly, Vol. 1, Iss. 1102, 2006-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Activities to promote quality use of medicines in New Zealand

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 472, 2005-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

A Perspective on New Zealand's Medicines Regulatory Environment

By Richardson R.   Shaw I.   Nolan S.  

International Journal of Pharmaceutical Medicine, Vol. 17, Iss. 1, 2003-01 ,pp. : 17-22

Adis International

Access to resources Recommend Favorite